10/30/2024
5:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form SC 13G | |
10/22/2024
3:18 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:19 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:21 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:22 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/22/2024
3:23 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
10/22/2024
3:17 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/18/2024
5:42 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:27 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:42 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:10 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:17 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
3:57 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/18/2024
4:00 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
4:06 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/15/2024
3:38 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/10/2024
7:36 PM | Ballal Rahul D. (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
7:38 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
7:39 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/09/2024
3:27 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/09/2024
3:16 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/08/2024
5:54 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:56 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:57 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/08/2024
5:58 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/04/2024
3:28 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/03/2024
5:43 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:44 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:45 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/03/2024
5:47 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/01/2024
6:53 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/30/2024
3:19 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/18/2024
3:17 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/03/2024
4:43 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/29/2024
5:36 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
6:48 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/19/2024
6:49 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/19/2024
3:32 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/19/2024
3:32 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
3:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
We recommended Nvidia in 2016, now we’re recommending this… (Ad) The Pentagon has just made a critical $7.7 billion move.
They're investing into one of the most controversial technologies the world has ever known…
A technology I’m calling “The AI Keystone”, because without it, the AI industry is doomed. Click here to watch his special investigative report into the controversial ‘AI Keystone’. |
08/02/2024
6:23 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:25 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:26 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/02/2024
6:22 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
6:31 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
6:33 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/31/2024
3:30 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/31/2024
3:31 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/29/2024
5:12 PM | 5AM Ventures VI, L.P. (Filed by)
Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form SC 13D/A | |
07/29/2024
4:39 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/29/2024
3:15 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/25/2024
3:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/17/2024
6:25 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
4:37 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/16/2024
4:34 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/15/2024
3:12 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
3:48 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/12/2024
3:48 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Patel Anish (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/03/2024
3:31 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2024
7:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
3:35 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
3:38 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/25/2024
2:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2024
6:20 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:12 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/17/2024
3:24 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/10/2024
5:46 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
4:54 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2024
4:56 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/29/2024
3:06 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K/A | |
05/29/2024
3:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Lyssikatos Joseph P (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/28/2024
4:45 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Hohl Benjamin (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/28/2024
4:29 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Kintz Samuel (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/20/2024
6:46 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/20/2024
4:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Gupta Rishi (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
2:08 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/17/2024
2:11 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED CAPITAL LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/17/2024
2:04 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
ORBIMED ADVISORS LLC (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
6:29 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/16/2024
4:23 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
4:23 PM | Enliven Therapeutics, Inc. (Subject)
Enliven Therapeutics (Subject)
Heyman Richard A. (Reporting)
Heyman Richard A. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/14/2024
3:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/14/2024
3:10 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
6:35 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/08/2024
7:40 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Patel Anish (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/07/2024
5:58 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2024
6:02 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2024
6:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/30/2024
11:15 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form EFFECT | |
04/30/2024
3:16 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form 424B3 | |
We recommended Nvidia in 2016, now we’re recommending this… (Ad) The Pentagon has just made a critical $7.7 billion move.
They're investing into one of the most controversial technologies the world has ever known…
A technology I’m calling “The AI Keystone”, because without it, the AI industry is doomed. Click here to watch his special investigative report into the controversial ‘AI Keystone’. |
04/29/2024
5:50 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2024
3:11 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
3:16 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form ARS | |
04/18/2024
3:44 PM | Enliven Therapeutics, Inc. (Filer)
Enliven Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/15/2024
6:02 PM | Collins Helen Louise (Reporting)
Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:03 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Heyman Richard A. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:04 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Hohl Benjamin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:05 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Kintz Samuel (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/15/2024
6:06 PM | Enliven Therapeutics, Inc. (Issuer)
Enliven Therapeutics (Issuer)
Lyssikatos Joseph P (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
